Evaluation of salivary adiponectin profile in obese patients

E Nigro1, P Piombino2, O Scudiero3

  • 1CEINGE-Biotecnologie Avanzate Scarl, Via Salvatore 486, 80145 Napoli, Italy.

Peptides
|December 8, 2014
PubMed

Insights

Obesity is linked to altered adiponectin levels. This study found higher total and specific adiponectin oligomers in obese individuals

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Biochemistry

Background:

  • Obesity is a global health issue characterized by chronic inflammation.
  • Adipokines, like adiponectin, play key roles in energy metabolism and inflammation.
  • Adiponectin exists in various oligomeric forms (HMW, MMW, LMW), with HMW being the most active.

Purpose of the Study:

  • To investigate total adiponectin and its oligomeric profile in saliva of obese individuals.
  • To compare salivary adiponectin oligomerization with serum levels.
  • To explore saliva as a potential biomarker for metabolic disorders.

Main Methods:

  • Analysis of total adiponectin and oligomeric profile in saliva samples.
  • Comparison between 27 obese patients and 27 age/sex-matched controls.
  • Size-exclusion chromatography (FPLC) to analyze adiponectin oligomerization in serum and saliva.

Main Results:

  • Obese patients showed slightly higher levels of total, HMW, and LMW salivary adiponectin compared to controls.
  • Salivary HMW adiponectin oligomers exhibited higher molecular weight than serum counterparts, indicating more complex structures (S-HMW).

Conclusions:

  • Salivary adiponectin and its oligomeric profile may serve as a promising biomarker for metabolic diseases.
  • Saliva offers a non-invasive method for assessing adiponectin, a key metabolic regulator.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
425
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
351
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
310